

# PCL Department Publications - 2005

## "A,B,C,D"

**Brands, B.**, Leslie, K., Catz-Biro, L. and Li, Selina, S. Heroin Use and Barriers to Treatment in Street Involved Youth. *Addiction Res Theory* 13:477-487,2005.

---

Murphy, P, Likhodii, SS, Hatamian, M, and **Burnham, WM**. The effect of the ketogenic diet on the activity level of Wistar rats. *Pediatric Res* 57:353-357, 2005.

Abdelmalik, PA, Burnham WM, and Carlen, PL. Increased Seizure Susceptibility of the Hippocampus Compared with the Neocortex of the Immature Mouse Brian in vitro. *Epilepsia* 46:356-366, 2005

Nylen, K. Likhodii, S, Abdelmalik, PA, Clarke, J and **Burnham, WM**. A Comparison of the Ability of a 4:1 Ketogenic Diet and a 6.3:1 Ketogenic Diet to Elevate Seizure Thresholds in Adult and Young Rats. *Epilepsia* 46:1-7, 2005

Edwards, HE, Vimal, S and **Burnham, WM**. The acute anticonvulsant effects of deoxycorticosterone in developing rats: Role of metabolites and mineralocorticoid receptor responses. *Epilepsia* 46:1888-1897, 2005

Vessal, M, Dugani, CB, Solomon, DA, **Burnham, WM**, Ivy, GO. Might astrocytes play a role in maintaining the seizure-prone state? *Brain Res* 1044:190-196, 2005

Hewapathirane, S, **Burnham, WM** Propagation of amygdala-kindled seizures to the hippocampus in the rat: electroencephalographic features and behavioural correlates. *Neuroscience Research (Japan)* 53:369-75, 2005

Ohayon, EL, Kalitzin, S, Suffczynski P, Jin, FY, Tsang, PW, **Burnham, WM**, Kwan, HC. Charting Epilepsy by Searching for Intelligence in Network Space with the Help of Evolving Autonomous Agents. *J Physiology (Paris)* 98:507-529, 2005

**Burnham, WM**, Lonsdale, D, Shahzamani, A, Perez-Cruz, C. and Edwards, EH. Development of New Anticonvulsants using the Kindling Model . In Corcoran, M. and Moshe, S.L., (eds) *Kindling 6.*, Plenum Press, New York, pp. 325-332, 2005

Thompson, MD, **Burnham WM**, Cole DE. The G protein-coupled receptors: pharmacogenetics and disease. *Crit. Rev. Clin. Sci.*, 42:311-392, 2005.

---

Pratt CM, **Dorian P**, Al-Khalidi HR, et al. Design of the Shock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator. *Am J Cardiol* 95:274-276,2005.

Nanthakumar K, Newman D, Paquette M, **Dorian P**. A systematic evaluation of the determinants of defibrillation efficacy. *Heart Rhythm* 2:36-41,2005.

Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, **Dorian P**, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation (CARAF). *Am Heart J* 149:489-496, 2005.

Simpson CS, Hoffmaster B, **Dorian P**. Downward delegation of implantable cardioverter defibrillator decision-making in a restricted resource environment: The pitfalls of bedside rationing. *Can J Cardiol*; 21:595-9, 2005.

Tang AS, Ross H, Simpson CS, Mitchell LB, **Dorian P**, et al. Implantable cardioverter defibrillator use in Canada. *Can J Cardiol*; 21(Suppl A):11-18,2005.

Simpson CS, O'Neill BJ, Sholdice MM, **Dorian P**, et al. Implantable cardioverter defibrillators in Canada: Waiting times and access to care issues. *Can J Cardiol*; (Suppl A):19-24,2005.

**Dorian P**, Talajic M, Tang A. Implanted cardioverter defibrillators for the prevention of sudden death. *Can J Cardiol*; (Suppl A):31-36,2005.

Gabor JY, Newman DM, Barnard-Roberts V, Korley V, Mangat I, **Dorian P**, Hanly PJ. Improvement in Cheyne-Stokes respiration following cardiac resynchronization therapy. *Eur Respir J* 26:95-100,2005.

Morrison LJ, **Dorian P**, Long J, et al. Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT). *Resuscitation* 66:149-157,2005.

Zhong JQ, **Dorian P**. Epinephrine and vasopressin during cardiopulmonary resuscitation. *Resuscitation*66:263-269,2005.

Strauss MH, **Dorian P**, Verma S. Fish oil supplementation and arrhythmias (Letter to Editor). *JAMA* 294:2165 2005.

Mangat I, Bokhari F, Newman D, Greene M, Korley V, **Dorian P**. Response to Letter to the Editor written by Boriani regarding article by Bokhari et al. *Circulation* 111:e26,2005.

Hong MF, **Dorian P**. Update on advanced life support and resuscitation techniques. *Curr Opin Cardiol* 20:1-6,2005.

**Dorian P.** Antiarrhythmic action of beta-blockers: Potential mechanisms. *J Cardiovasc Pharmacol Ther* 10:S15-22,2005.

Pinter A, **Dorian P.** Approach to antiarrhythmic therapy in patients with ICDs and frequent activations. *Curr Cardiol Rep* 7:376-381,2005.

Skanes AC, **Dorian P.** Atrial Fibrillation. Chapter 1, Etiology and initial investigation. *Can J Cardiol* 21(Suppl B):11-14,2005.

**Dorian P,** Connors SP. Atrial Fibrillation. Chapter 4, Pharmacological and non-pharmacological methods for rate control. *Can J Cardiol* 21(Suppl B):26-30,2005.

---

## "E,F,G"

Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, L. **Endrenyi L,** and Reist C. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements. A prospective dose-adjusted drug interaction strategy. *J. Clin. Psychopharmacol.* 25:170-174,2005.

Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, **Endrenyi L,** and Reist C. Does N-desmethyloanzapine increase, or reduce, the risk for antipsychotic-induced metabolic syndrome? *J. Clin. Psychopharmacol.* 25:627-628,2005.

Ozdemir V, Kalow W, Tothfalusi L, Bertilsson L, **Endrenyi L,** and Graham JE. Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. *Current Pharmacogen.* 3:53-71,2005.

---

Hasbi A, O'Dowd BF and **George SR.** A G protein coupled receptor for estrogen- The end of the search? *Mol Interventions,* 5:158-161, 2005.

So CH, Varghese G, Curley KJ, Kong MMC, Ji XD, Nguyen T, O'Dowd BF and George SR. D1 and D2 dopamine receptors form heterooligomers and co-internalize following selective activation of either receptor. *Mol Pharmacol* 68:568-578, 2005.

O'Dowd BF, Ji X, Alijaniam M, Rajaram RD, Kong MMC, Rashid A, Nguyen T and **George SR.** Dopamine Receptor Oligomerization Visualized in Living Cells. *J Biol Chem* 280: 37225-37235, 2005.

Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, **George SR.** A Role for the Distal Carboxyl Tails in Generating the Novel Pharmacology and G Protein Activation Profile of Mu and Delta Opioid Receptor Heterooligomers. *J Biol Chem* 280:38478-38488, 2005.

Karasinska JM, **George SR**, Cheng R and O'Dowd BF. Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behavior and cocaine-induced locomotor activity, reward and CREB phosphorylation. *Eur J Neuroscience* 22:1741-1750, 2005.

Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'Dowd BF, **George SR**, et al. Dopamine supersensitivity correlates with D2high states, implying many paths to psychosis. *Proc Natl Acad Sci USA* 102:3513-3518, 2005.

**George SR** and O'Dowd B.F. (editors). *G Protein-Coupled Receptor-Protein Interactions. Receptor Biochemistry and Methodology Series*. Wiley-Liss, 2005.

Kong MMC, So CH, O'Dowd BF and **George SR**. The role of oligomerization in G protein couples receptor maturation. In Devi LA (ed) *The G Protein-Coupled Receptors Handbook*. Human Press, pp. 287-307, 2005.

---

Okey AB, Harper PA, **Grant DM** & Hill RP. Environmental carcinogenesis. In I Tannock, RP Hill, R Bristow & L Harrington (eds) *The Basic Science of Oncology*, 4th Edition, McGraw-Hill, New York pp. 25-48, 2005.

---

Konarski JZ, McIntyre RS, **Grupp LA**, et al: In the cerebellum relevant in the circuitry of neuropsychiatric disorders? *J Psychiatry Neurosci* 30:178-186, 2005.

McIntyre RS, Konarski JZ, Mancini DA, et al: Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. *CMAJ* 173:1327-1334, 2005.

---

## "H,I,J"

**Haas DA**. Management of medical emergencies in the dental office: Conditions in each country, the extent of treatment by the dentist. *J Jp Dent Soc Anesthes* 33:11-16, 2005.

Chanpong B, **Haas DA**, Locker D. Need and demand for sedation or general anesthesia in dentistry: A National Survey of the Canadian Population. *Anesth Progr* 52:3-11, 2005.

Barnett GA, Pynn BR, Wood RE, Sieswerda L, **Haas DA**. Mandibular anesthesia landmarks: a comparison of Canadian aboriginals and Caucasians. *Oral Health*,95:10-14, 2005

**Haas DA**. Drugs in Dentistry. *Compendium of Pharm Specialties*, L26-29, 2005.

---

Kuang D, Yao Y, Lam J, Tsushima RG, and **Hampson DR**. Cloning and characterization of a Family C orphan G-protein coupled receptor. *J Neurochem* 93, 383-391,2005.

Wang X, Ai J, **Hampson DR**, and Snead OC. Altered Glutamate and GABA Release within Thalamocortical Circuitry in mGluR4 Knockout Mice. *Neuroscience* 134,1195-1203, 2005.

---

Okey AB, Boutros PC, **Harper PA**: Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. *Pharmacog Genomics* 15:371-379,2005.

Xu H, Rajesan R, **Harper P**, et al: Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. *Br J Pharmacol* 146:296-305, 2005.

---

Ivakine EA, Fox CJ, Paterson AD, Mortin-Toth SM, Walton DS, Aleksa K, **Ito S**, Danska JS. Sex specific effect of insulin-dependent diabetes 4 on diabetes pathogenesis in the nonobese diabetic mouse. *J Immunol* 174:7129-7140,2005

Aleksa K, Matsell D, Krausz K, Gelboin H, **Ito S**, Koren G. Cytochrome P450 3A and 2B6 in the developing kidney; Implications for Ifosfamide Nephrotoxicity. *Pediatric Nephrol* 20:872-885,2005.

Xu H, Rajesan R, Harper P, Kim RB, Lonnerdal B, Yang M, Uematsu S, Hutson J, Watson-MacDonell J, **Ito S**. Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. *Br J Pharmacology* 146:296-305,2005.

---

## "K"

**Kalant H**. Effects of food and body composition on blood alcohol levels. In: Preedy VR, Watson RR (eds), *Comprehensive handbook of alcohol related pathology*, Vol 1. Elsevier Science, London, pp 88-101, 2005.

---

**Kalow W**, Meyer UA, Tyndale RF. (eds) *Pharmacogenomics. Drugs and the Pharmaceutical Sciences series*, Vol 156, Taylor & Francis, New York, 2005

**Kalow W**. A pharmacogeneticist's look at drug effects and the drug development process: an overview. *Expert Opin Pharmacother* 6:1299-1303,2005.

**Kalow W.** Pharmacogenomics: historical perspective and current status. *Methods Mol Biol* 311: 3-15, 2005.

---

Ahn E, Kapur B, **Koren G:** Study on circadian variation in folate pharmacokinetics. *Can J Clin Pharmacology* 12:4-9, 2005.

Aleksa K, Halachmi N, Ito S, **Koren G:** A tubule cell model for ifosfamide nephrotoxicity. *Can J Physiol Pharmacol* 83:499-508, 2005.

Aleksa K, Matsell D, Ito S, **Koren G:** Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. *Ped Nephrology* 20:872-885, 2005.

Berlin CM, LaKind JS, Fenton SE, **Koren G,** et al: Technical workshop on human milk surveillance and bioMonit for environmental chemicals in the US. *J Tox Env Health* 68:1825-1831, 2005.

Boskovic R, Gargaun L, Oren D, Djulus J, **Koren G:** Pregnancy outcome following high doses of Vitamin E supplementation. *Reproductive Tox* 20:85-88, 2005.

Boskovic R, Wide R, Wolpin J, Bauer DJ, **Koren G:** The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology* 65:807-811, 2005.

Caprara DL, Brien JF, Iqbal U, Reynolds JN, Klein J, **Koren G:** A guinea pig model for the identification of in utero alcohol exposure using fatty acid ethyl esters in neonatal hair. *Pediatric Res* 58:1158-1163, 2005.

Caprara DL, Klein J, **Koren G:** Baseline measures of fatty acid ethyl esters in hair of neonates born to abstaining social drinking mothers. *Ther Drug Monit* 27:811-5, 2005.

Finkelstein Y, Schechter T, Rokach B, **Koren G:** Increase in movie stars' smoking on the big screen and its effect on teen smoking. *Ther Drug Monit* 27:547-548, 2005.

Chan B, Einarson A, **Koren G:** Effectiveness of bupropion for smoking cessation during pregnancy. *J Addict Disorder* 24:19-23, 2005.

Chun-Fai-Chan B, **Koren G,** et al: Pregnancy outcome of women exposed to bupropion during pregnancy *Am J Obstetr Gynecol* 192:932-936, 2005.

Cohen-Kerem R, Railton C, Oren D, Lishner M, **Koren G:** Pregnancy outcome following non-obstetric surgical intervention. *Am J Surgery* 190:467-73, 2005.

Eisner MD, Klein J, Hammond SK, **Koren G,** Lactao G, Iribarren C: Directly measured second hand smoke exposure and asthma health outcomes. *Thorax* 60:814-821, 2005.

- Feig DS, Briggs GG, Kraemer JM, Ambrose PJ, Klein J, **Koren G**: Transfer of glyburide and glipizide into breast milk. *Diabetes Care* 28:1851-1855, 2005.
- Finkelstein Y, Chitayat D, Schechter T, Toi A, **Koren G**: Warfarin embryopathy following low-dose maternal exposure. *J Obstetr Gynecol* 27:702-706, 2005.
- Finkelstein Y, Nurmohamed L, Avner M, Benson LN, **Koren G**: Clopidogrel use in children. *J Pediatrics* 147:657-661.
- Florescu A, **Koren G**: Nonsteroidal anti-inflammatory drugs for rheumatoid arthritis during pregnancy. *Can Fam Physician* 51:961-962, 2005.
- Kalra S, Einarson A, **Koren G**: Taking antidepressants during late pregnancy. *Can Fam Physician* 51:1077-1078, 2005.
- Djulus J, Moretti M, **Koren G**: Marijuana use and breastfeeding. *Can Fam Physician* 51:349-350, 2005.
- Many A, **Koren G**: Low MW heparins during pregnancy. *Can Fam Physician* 51:199-201.
- Gareri J, Chan D, Klein J, **Koren G**: Motherisk Team. Screening for fetal alcohol spectrum disorder. *Can Fam Physician* 51:33-34, 2005.
- Gilbert CJ, **Koren G**: Safety of metformin use during the first trimester. *Can Fam Physician* 51:1070-1073, 2005.
- Gilbert C, Mazzotta P, Loebstein R, **Koren G**: Fetal Safety of drugs used in the treatment of allergic rhinitis. *Drug Safety* 28:707-19.
- Groner JA, Hoshaw-Woodard S, **Koren G**, Klein J, Castile R: Screening for children's exposure to environmental tobacco smoke in a pediatric primary care setting. *Arch Ped Adolescent Med* 159:450-455, 2005.
- Han JY, Nava-Ocampo AA, **Koren G**: Unintended pregnancies and exposure to potential human teratogens. *Birth Defects Res A Clin Mol Teratol* 73:245-248, 2005.
- Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, **Koren G**, et al: A survey of pregnant women using isotretinoin. *Op cit* 73:881-887, 2005.
- Hard ML, Abdolell M, Robinson BH, **Koren G**: Gene-expression analysis after alcohol exposure in the developing mouse. *J Lab Clin Med* 145:47-54, 2005.
- Hemels ME, Einarson A, **Koren G**, Lanctot KL, Einarson TR: Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. *Annals Pharmacotherapy* 39:803-809, 2005.

Jacqz-Aigrain E, **Koren G**: Effects of drugs on the fetus. *Semin Fetal Neonatal Med* 10:139-147, 2005.

**Koren G**: Congenital varicella syndrome in the third trimester. *Lancet* 366:1591-1592, 2005.

**Koren G**, Matsui D, et al: Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? *CMAJ* 172:1457-1459, 2005.

**Koren G**, Matsui D, Einarson A, Knopper D, Steiner M: Using antidepressants during pregnancy. *CMAJ* 173:1205-1206, 2005.

**Koren G**, Piwko C, Ahn E, et al: Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. *J Obstetr Gynecol* 25:241-244, 2005.

Kozer E, Scolnik D, **Koren G**: Using a preprinted order sheet to reduce prescription errors in a pediatric emergency department. *Pediatrics* 116:1299-1302, 2005.

LaKind JS, Brent RL, Dourson ML, Kacew S, **Koren G**, Sonawane B, Tarzian AJ, Uhl K: Human milk bioMonit data. *J of Tox Env Health* 68:1713-1769, 2005.

McKenna K, **Koren G**, et al: Pregnancy outcome of women using atypical antipsychotic drugs. *J Clin Psychiatry* 66:444-449, 2005.

Mills E, Montori V, Perri D, Phillips E, **Koren G**: Natural health product-HIV drug interactions: a systematic review. *Int J STD AIDS* 16:181-186, 2005.

Mirabella G, **Koren G**, Rovet J: Development of contrast sensitivity in infants with prenatal and neonatal thyroid hormone insufficiencies. *Pediatric Res* 57:902-907, 2005.

Pinto N, Halachmi N, Verjee Z, Woodland C, Klein J, **Koren G**: Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. *Pediatric Res* 58:1284-1289, 2005.

Moretti ME, Bar-Oz B, Fried S, **Koren G**: Maternal hyperthermia and the risk for neural tube defects in offspring. *Epidemiology* 16:216-219, 2005.

Nava-Ocampo AA, Pastrak A, Cruz T, **Koren G**: Pharmacokinetics of high doses of cyanocobalamin administered by intravenous injection for 26 weeks in rats. *Clin Exp Pharmacol Physiol* 32:13-18, 2005.

O'Brien L, Taddio A, Lyszkiewicz DA, **Koren G**: A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain. *Pediatric Drugs* 7:41-54, 2005.

Railton CJ, Kapur B, **Koren G**: SubTher risperidone serum concentrations in an adolescent during hemodialysis. *Ther Drug Monit* 27:558-561, 2005.



Sarkar M, Djulus J, **Koren G**: When a cocaine-using mother wishes to breastfeed: proposed guidelines. *Ther Drug Monit* 27:1-2, 2005.

Schechter T, Finkelstein Y, Doyle J, **Koren G**: Pregnancy after stem cell transplantation. *Can Fam Physician* 51:817-818, 2005.

Schechter T, Finkelstein Y, **Koren G**: Pregnant “DES daughters” and their offspring. *Can Fam Physician* 51:493-494, 2005.

Shrim A, Berger H, Kingdom J, Hamoudi A, Shah PS, **Koren G**: Prolonged exposure to ACE inhibitors during pregnancy. *Can Fam Physician* 51:1335-1337, 2005.

Shrim A, **Koren G**: Tumour necrosis factor alpha and use of infliximab. Safety during pregnancy. *Can Fam Physician* 51:667-668, 2005.

Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, **Koren G**: Citalopram use in pregnancy. *Am J Obstetr Gynecol* 193:2004-2009.

Stempak D, Bukaveckas BL, Linder M, **Koren G**, Baruchel S: Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. *Clin Pharmacol Ther* 78:309-710, 2005.

Stempak D, Gammon J, Halton J, **Koren G**, Baruchel S: Modulation of celecoxib pharmacokinetics by food in pediatric patients. *Op cit* 77:226-228, 2005.

Sung L, Hayden J, Greenberg ML, **Koren G**, et al: Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. *J Clin Epidemiology* 58:261-268, 2005.

Taddio A, Soin HK, Schuh S, **Koren G**, Scolnik D: Liposomal lidocaine to improve procedural success rates and reduce pain among children. *CMAJ* 172:1691-1695, 2005.

Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, **Koren G**: Understanding drugs in children: pharmacokinetic maturation. *Ped Rev* 26:321-328, 2005.

Till C, Westall CA, **Koren G**, Nulman I, Rovet JF: Vision abnormalities in young children exposed prenatally to organic solvents. *Neurotoxicology* 26:599-613, 2005.

---

## "L"

Herrmann N, **Lanctôt KL**. Do atypical antipsychotics cause stroke? *CNS Drugs* 19:91-103, 2005.

Herrmann N, **Lanctôt KL**, Mamdani M. Psychotropic medication and stroke outcome. *Am J Psychiatry* 162:1027-1028, 2005.

Hemels MEH, Einarson A, Koren G, **Lancôt KL**, Einarson T. Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-analysis. *Ann Pharmacother* 39:803-809, 2005.

**Lancôt KL**, Herrmann N. Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer's disease. *Evid Based Ment Health* 8:15, 2005.

Glass J, **Lancôt KL**, Herrmann N, Sproule BA, Busto UE. Risk-benefit relationship of sedative use in elderly insomniacs: A meta-analysis. *Br Med J* 331:1169-1175, 2005.

Mittmann N, Craven BC, Gordon M, MacMillan RDH, Hassouna M, Raynard W, Kaiser A, **Lancôt KL**, Tarride, JE. Erectile dysfunction in spinal cord injury: a cost-utility analysis. *J Rehab Med* 37:358-364, 2005.

---

Funk Z, Li, Fletcher PJ and **Lê AD**. Effects of injections of 8-OH-DPAT or muscimol in the median raphe nucleus on c-fos mRNA in the rat brain. *Neuroscience* 131:475-479, 2005.

Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, Lê AD, et al. Stress enhancement of craving during sobriety: a risk for relapse. *Alcoholism: Clin Exp Res* 25:185-195, 2005.

Turek VF, Tsivkovskaia NO, Hyytia P, Harding S, **LêAD**, Ryabinin AE. Urocortin 1 Expression in Five Pairs of Rat Lines Selectively Bred for Differences in Alcohol Drinking. *Psychopharmacology* 181:511-517, 2005.

Erb S, Funk D and **Lê AD**. Cocaine pre-exposure enhances CRF-induced of c-fos mRNA in the central nucleus of the amygdala: an effect parallels the effects of cocaine pre-exposure on CRF-induced locomotor activity. *Neuroscience Lett*. 383:209-214, 2005

FunkD, HardingS, Juzysch W, **Le AD**. Effects of unconditioned and conditioned social defeat on alcohol self-administration and reinstatement of alcohol seeking in rats. *Psychopharmacology* 181: 341-289, 2005.

**Lê AD**, Funk D. Effects of serotonergic compounds on alcohol intake and relapse: Preclinical data. In: Spanagel R & Mann K (eds), *Drugs for relapse prevention in: Alcoholism, Milestones in Drug Therapy*, Birkhauser, pp 95-106, 2005.

---

## "M"

Erdeljan P, Andrews MH, **MacDonald JF**, Matthews SG. Glucocorticoids and serotonin alter glucocorticoid receptor mRNA levels in fetal guinea-pig hippocampal neurons, in vitro. *Reprod Fertil Dev*. 17:743-749, 2005.

Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, Roder JC, Orser BA, **MacDonald JF**. Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. *J Neurosci* 25:11374-11384, 2005.

Orser BA, Caraiscos VB, You-Ten EK, Cheng VY, Newell JG, **MacDonald JF** The  $\gamma$ 5 GABAA receptor subunit confers resistance to isoflurane inhibition. *Int Congr Series*, 1283:189-192, 2005.

Orser, BA, Caraiscos VB, Elliott E, Cheng VY, Newell JG, **MacDonald JF**. (2005) Anesthetic sensitivity is reduced in hippocampal pyramidal neurons from GABAA receptor  $\alpha$ 5 subunit null mutant mice. *Int Congr Series*, 1283:38-42, 2005.

**MacDonald JF**, Suhas A. Kotecha, et al. NMDA receptors from protein-protein interactions to transactivation. In Stanton PK, Bramham C, and Scharfman HE (eds.) *The Transsynaptic Dialogue in Synaptic Plasticity*, Springer Science, 2005

**MacDonald JF**, Xiong Z-G, Wei W.L., et al. NMDA and TRPM7 Cation Channels: Initiation of Stroke-Induced Cell Death. *Cell Science Reviews*, 2005.  
[Http://www.cellscience.com/reviews4/NMDA\\_TRPM7\\_Cation\\_Channels\\_Initiation\\_Stroke-Induced\\_Cell\\_Death.html](http://www.cellscience.com/reviews4/NMDA_TRPM7_Cation_Channels_Initiation_Stroke-Induced_Cell_Death.html)

---

**McIntyre RS** (PA), Brecher M, Raulsson B. Quetiapine as Monotherapy for Bipolar Mania. A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Trial. *Eur Neuropsychopharmacol* 15:573-585, 2005.

**McIntyre RS** (SRA), Konarski J, Mancini D, et al. Validation of the HAMD-7 Scale: A Metric for Depression Severity and Remission in Primary Care. *CMAJ* 173:1327-1334, 2005.

Poulin MJ, Cortese L, Williams R, Phil M, Wine N, **McIntyre RS** (C). Atypical Antipsychotics in Psychiatric Practice: Practical Implications for Clinical Monitoring. *Can J Psychiatry* 50:555-562, 2005.

**McIntyre RS**, Kusumakar V. Open-Label Adjunctive Topiramate in the Treatment of Unstable Bipolar Disorder. *Can J Psychiatry* 50:415-22, 2005.

**McIntyre RS**, Kennedy SH. Bipolar Disorder and Diabetes Mellitus: Epidemiology, Etiology, and Treatment Implications. *Ann Clin Psychiatry*, 17:83-93, 2005

**McIntyre RS** (PA), Konarski J.Z, Leiter L., et al. Schizophrenia, Glycemia and Antipsychotic Medications: An Expert Consensus Review. *Can J Diabetes*, 29:113-121, 2005.

**McIntyre RS** (PA), Mancini D.A., Pearce MM., Silverstone P., Chue P., Misener V.L., Konarski J.Z. Mood and Psychotic Disorders and Type 2 Diabetes: A Metabolic Triad. *Op cit* 29:122-132, 2005.

Konarski JZ, **McIntyre RS** (TS), Grupp LA, Kennedy SH. Is the Cerebellum Relevant in the Circuitry of Neuropsychiatric Disorders? *J Psychiatry Neuroscience*, 30:178-86, 2005.

**McIntyre RS** (PA), Konarski JZ. Duloxetine: Pharmacoeconomic Implications of an Antidepressant that Alleviates Painful Physical Symptoms. *Expert Opinion Pharmacotherapy*, 6:707-713, 2005.

**McIntyre RS** (PA), Konarski JZ. Tolerability Profiles of Atypical Antipsychotics in the Treatment of Bipolar Disorder. *J Clin Psychiatry*, 66(Suppl 3):28-36, 2005.

**McIntyre RS** (SRA), Konarski JZ, Grigoriadis S, Fan NC, Mancini DA, Fulton KA, Stewart DE, Kennedy SH. Hormone Replacement Therapy and Antidepressant Prescription Patterns: A Reciprocal Relationship. *CMAJ* 172:57-59, 2005.

---

Lai LP, **Mitchell J**. Indian Hedgehog: Its roles and regulation in endochondral bone development. (Rev) *J Cellular Biochem*. 96:1163-1173; 2005.

Cheung R, Erclik MS, **Mitchell J**. 1,25-dihydroxyvitamin D3 stimulated protein kinase C phosphorylation of type VI adenylyl cyclase inhibits parathyroid hormone signal Transduction in rat osteoblastic UMR 106-01 cells. *J Cell Biochem*. 94:1017-1027; 2005.

Erclik MS, **Mitchell J**. Activation of the insulin-like growth factor binding protein-5 promoter by parathyroid hormone in osteosarcoma cells requires activation of an activated protein-2 element. *J Mol Endocrinol*. 34:713-722; 2005.

Cheung R, Erclik MS, **Mitchell J**. Increased expression of G11? in osteoblastic cells enhances parathyroid hormone activation of phospholipase C and AP-1 regulation of matrix metalloproteinase-13 mRNA. *J Cell Physiol*. 204:336-343; 2005.

Lai LP, DaSilva KA, **Mitchell J**. Regulation of Indian hedgehog mRNA levels in chondrocytic cells by ERK1/2 and p38 mitogen-activated protein kinases. *J Cell Physiol*. 203:177-185;2005.

---

Seung SJ, **Mittmann N**. Urgent care costs of uncontrolled asthma in Canada 2004. *Can Respir J* 12:435-436, 2005.

Mitchell J, Craven BC, Gordon M, MacMillan RDH, Hassouna M, Raynard W, Kaiser A, Lanctot KL, Tarride, JE. Erectile dysfunction in spinal cord injury: a cost-utility analysis. *J Rehab Med* 37:358-364, 2005.

---

Canil C, **Moore MJ**, Winquist E, et al. Phase II Study of Two Doses of Gefitinib (Iressa?) in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. *J Clin Oncol* 23:455-460, 2005.

Ringash J, Khaksar S, Oza A, Couture J, Japp B, **Moore MJ**, et al. Post-operative Radiochemotherapy for Gastric Cancer. *Clin Oncol* 17:91-95, 2005.

Zhang W, Siu LL, **Moore MJ**, Chen EX. Simultaneous Determination of OSI-774 and its major metabolite OSI-420 in Human Plasma by Using HPLC with UV Detection. *J Chromatogr* 814:143-147, 2005.

Lapointe R, Létourneau R, Steward W, Hawkins R, Batist G, Vincent M, Whittom R, Eatock M, Jolivet J, **Moore MJ**. Phase 2 Study of Troxacitabine in Chemotherapy Naïve Patients with Advanced Cancer of the Pancreas. *Ann Oncol* 16:289-93, 2005.

Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, **Moore MJ**. Combining Capecitabine and Gemcitabine (GemCap) in Patients with Advanced Biliary cancer: A Phase II Trial. *J Clin Oncology* 23:2332-2338, 2005.

Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, **Moore MJ**, et al. Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. *Eur J Cancer* 41:523-30, 2005.

---

## "N"

Shaked Y, Cervi D, **Neuman M**, et al. The splenic microenvironment is a source of pro-angiogenesis / inflammatory mediators accelerating the expansion of murine erythroleukemic cells. *Blood*. 105:4500-4507, 2005.

---

Hipólido DC, Moreira KM, Wilson AA, Barlow KBL, **Nobrega JN** and Tufik S. Distinct effects of sleep deprivation on binding to serotonin and norepinephrine transporters in rat brain. *Progr Neuro-Psychobiol Biol Psychiatry* 29:297-303, 2005.

Turrone P, Remington G, Kapur S and **Nobrega JN**. Continuous but not intermittent olanzapine infusion gives rise to vacuous chewing movements (VCMS) in rats. *Biol Psychiatry* 57:406-411, 2005.

Andersen KL, Papale LA, Hipólido DC, **Nobrega JN** and Tufik S. Involvement of dopamine receptors in cocaine-induced genital reflexes after paradoxical sleep deprivation. *Behav Brain Res* 160:44-50, 2005.

Hellemans KGC, **Nobrega JN** and Olmstead MC. Early environmental experience alters ethanol-induced cognitive impulsivity: Relationship to forebrain 5HT1A receptor binding. *Behav Brain Res* 159:207-220, 2005.

Dubiela FP, de Oliveira MGM, Moreira KD, **Nobrega JN**, et al. Learning deficits induced by sleep deprivation and recovery are not associated with altered [3H]muscimol and [3H]flunitrazepam binding. *Brain Res* 1037:157-163, 2005.

Natesan S, VanderSpek S, **Nobrega JN**, McLlelland RA and Kapur S. Converting Loxapine into an atypical antipsychotic in animal models -- the critical role of D2 affinity and occupancy. *Schizophrenia Res* 77:189-199, 2005.

**Nobrega JN**, Barlow KL, et al. Decreased adenosine receptor binding in brains of dystonic dtsz mutant hamsters. *Neuroscience* 134:33-38, 2005.

D'Almeida V, Hipólido DC, Raymond R, Barlow KL, Parkes J-H, Pedrazzoli M, Tufik S and **Nobrega JN**. Opposite effects of sleep rebound on orexin OX1 and OX2 receptor expression in rat brain. *Mol Brain Res* 136:148-157, 2005.

---

## "O"

Leung C, Chan K, Poon R and **O'Brien PJ**. Role of carbonyl metabolizing enzymes in the anesthesia and hepatotoxicity induced by chloral hydrate and tribromoethanol in vivo and in vitro. In: Weiner H, Plapp B, Lindahl R and Maser E (eds), *Enzymology and Molecular Biology of Carbonyl Metabolism* 12. Purdue University Press, West Lafayette, p 208-216, 2005.

Chan K, Leung C, Poon R and **O'Brien PJ**. Role of carbonyl metabolizing enzymes in the hepatocyte cytotoxicity of chloral hydrate and tribromoethanol anesthetics. *Op cit.* p171-180, 2005.

Shangari N., Poon R. and **O'Brien PJ**. Hepatocyte methylglyoxal resistance is overcome by inhibiting aldo-keto reductases and glyoxalase I catalyzed metabolism. *Op cit.* p266-275, 2005.

**O'Brien PJ**, Poon R, Siraki AG, Shangari N. Aldehyde Sources, Metabolism, Molecular Toxicity Mechanisms and Possible Effects on Human Health. *CRC Crit Rev Toxicol* 35:609-662, 2005.

Shangari N, Depeint F, Furrer R, Bruce WR, **O'Brien PJ**. The effects of partial thiamin deficiency and oxidative stress (i.e., glyoxal and methylglyoxal) on the levels of alpha-oxoaldehyde plasma protein adducts in Fischer 344 rats. *FEBS Lett.* 579:5596-602, 2005.

Tafazoli S, Wright J, **O'Brien PJ**. Prooxidant and antioxidant activity of vitamin E analogues and troglitazone. *Chem Res. Toxicol* 18:1567-1574, 2005.

Remirez D, Tafazoli S, Delgado, Harandi AA, **O'Brien PJ**. Preventing hepatocyte oxidative stress cytotoxicity with *Mangifera indica* L extract (Vimang). *Drug Metab Drug Interactions* 21:19-30, 2005

Kovacic P, Shangari N, **O'Brien PJ**. Mechanism of Mitochondrial Uncouplers, Inhibitors and Toxins: Focus on Electron Transfer, Free Radicals, and Structure-Activity Relationships. *Current Med Chem* 12:2601-23, 2005.

Martin JW, Mabury S, **O'Brien PJ**. Metabolic products and pathways of fluorotelomer alcohols in isolated rat hepatocytes. *Chemico-Biol. Interactions* 155:165-180, 2005.

Siraki AG, Chevaldina T, **O'Brien PJ**. Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes. *Chemico-Biol. Interactions* 151:177-191, 2005.

Pourahmad J, Rabieli M, Jokar F, **O'Brien PJ**. A comparison of hepatocyte cytotoxic mechanisms for chromate and arsenite. *Toxicology* 206:449-460, 2005.

Shangari N, Chan TS, **O'Brien PJ**. Sulfation and glucuronidation of phenols: implications for coenzyme Q metabolism. *Methods in Enzymology* 200; Phase II: Conjugation enzymes, Glutathione transferases and Transport Systems (November 2005).

Chan TS, Shangari N and **O'Brien PJ**. The biosynthesis of ascorbate protects isolated rat hepatocytes from cumene hydroperoxide-mediated oxidative stress. *Free Radical Biol Med* 38:867-873, 2005.

**O'Brien PJ**, Spehar DD, Tafazoli S. Oxidative Stress mediated Idiosyncratic Drug Toxicity. *Drug Metabolism Reviews* 37:311-326, 2005.

**O'Brien PJ**, Siraki A. Accelerated Cytotoxicity Mechanism Screening using Drug Metabolizing Enzyme Modulators *Current Drug Metab* 6:101-109, 2005.

Tafazoli S and **O'Brien PJ**. Peroxidases: their role in drug metabolism and side effects. *Drug Discovery Today* 10:617-625, 2005.

---

Kong MMC, So CH, **O'Dowd, BF** and George SR The role of oligomerization in G protein coupled receptor maturation. In L.A. Devi (ed) *The G Protein-Coupled Receptors Handbook*, Humana Press, pp. 287-307, 2005.

Lee, DK, Saldivia, V, George, SR and **O'Dowd, BF**. Modification of the terminal residue of apelin-13 antagonizes its hypotensive response. *Endocrinology*, 146: 231-236, 2005.



**O'Dowd, BF**, Ji, X., Alijaniam, M, Rajaram, R,D, Kong, MM, Rashid, A, Nguyen, T, George, SR. Dopamine receptor oligomerization visualized in living cells. *J Biol Chem* 280:37225-37235, 2005.

Fan T, Hayawara N, Tse R, Nguyen T, Varghese G, **O'Dowd BF**, and George SR. A role for distal carboxyl tails in generating the novel pharmacology of G protein activation profile of mu and delta opioid receptors. *J Biol Chem* 280:38478-38488, 2005.

Karasinska, JM., George, SR, Cheng, R, **O'Dowd, BF**. Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. *Eur J Neuroscience* 22:1741-1750, 2005.

Hasbi, A, **O'Dowd, BF**, George, SR. A G protein-coupled receptor for estrogen: the end of the search? *Mol Interventions* 5:158-161, 2005.

So, CH, Varghese, G, Curley, KJ, Kong, MM, Alijaniam, M, Ji, X, Nguyen, T, **O'Dowd, BF**, George, SR. D1 and D2 dopamine receptors form heterooligomers and coinernalize after selective adaptation of either receptor. *Mol Pharmacol* 68:568-578, 2005.

Seeman, P, Weinshenker, D, Quirion, R, Srivastava, LK, Bhardwaj, SK, Grandy, DK, Premont, Rt., Sotnikova, TD, Boksa, P, El-Ghundi, M, **O'Dowd, BF**, George, SR, et al. Dopamine supersensitivity correlates with d2High states, implying many paths to psychosis. *Proc Nat Acad Sci USA* 102:3513-3518, 2005.

George and O'Dowd B (eds), *G protein Coupled Receptor-Protein Interactions Receptor Biochemistry and Methodology Series*. Wiley-Liss, 2005.

---

**Okey AB**, Franc MA, Moffat ID, Tijet N, Boutros, P, et al. Toxicological implications of polymorphisms in receptors for xenobiotic chemicals: the case of the aryl hydrocarbon receptor. *Toxicol Appl Pharmacol* 207:S43-S51, 2005.

**Okey AB**, Boutros PC & Harper PA. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. *Pharmacogenet Genomics* 15:371-379, 2005.

Boutros PC & **Okey AB**. Unsupervised pattern recognition: an introduction to the whys and wherefores of clustering microarray data. *Briefings Bioinform* 6:331-343, 2005.

Séguin B, Boutros PC, Li X, **Okey AB** & Uetrecht J. Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of "Danger". *Chem Res Toxicol* 18:1193-1202, 2005.

**Okey AB**, Harper PA, Grant DM & Hill RP. Environmental carcinogenesis. In I Tannock, RP Hill, R Bristow & L Harrington (eds) *The Basic Science of Oncology*, 4th Edition, McGraw-Hill, New York pp. 25-48, 2005.



**Okey AB.** Variability of Induction of Drug-metabolizing Enzymes in Humans. In: W Kalow, UA Meyer, RF Tyndale (eds) Pharmacogenomics, 2nd Edition, Drugs and Pharmaceutical Sciences Vol 156, Taylor & Francis, New York pp. 157-205, 2005.

---

## "P,Q"

Xiang Li, Qiao Na, Reynaud Denis, Abdelhaleem Mohamed and **Pace-Asciak CR.** The Hepoxilin Analog, PBT-3, inhibits the growth of K-562 CML Solid Tumours in vivo in Nude Mice. *In Vivo* 19:185-190, 2005.

Hanson, J, Rolin, S, Reynaud, D., Qiao, N, Kelley, Kinsella, BT, Masereel, B, **Pace-Asciak, C,** Pirote, B and Dogne, JM. In Vitro and In Vivo Pharmacological Characterization of BM-613, a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist. *J Pharmacol Exp Ther* 313: 293-301, 2005.

Xiang Li, Qiao, Na, Reynaud, Denis, Abdelhaleem, Mohamed and **Pace-Asciak, CR.** PBT-3, a hepoxilin stable analog, causes long term inhibition of growth of K562 solid tumours in vivo. *Biochem, Biophys. Res. Commun.* 338:158-160, 2005.

**Pace-Asciak, CR.** Novel eicosanoid pathways: on the discovery of prostacyclin/6-keto prostaglandin F1alpha and the hepoxilins. *Mol Neurobiology* 32:19-26, 2005.

---

Liu L, **Pang KS:** The roles of transporters and enzymes in hepatic drug processing. *Drug Metab. Dispos.* 33:1-7, 2005.

Ship NJ, Toprak A, Lai RP, Tseng E, Kluger R, **Pang KS.** Binding of acellular native and cross-linked human hemoglobins to haptoglobin : enhanced distribution and clearance in the rat. *Am. J. Physiol.* 288:G1301-G1309, 2005.

Chang C, **Pang KS,** Swaan PW, Ekins S: Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. *J. Pharmacol. Exp. Ther.* 314:533-541, 2005.

Liu L, Mak E, Tirona RG, Tan E, Novikoff PM, Wang PJ, Wolkoff AW, **Pang KS:** Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver. *J. Pharmacol. Exp. Ther.* 315:433-448, 2005.

Fischer HC, Liu L, Papa E, **Pang KS,** Chan WCW. Exploring the interactions of quantum dots with whole blood components. *SPIE Proceeding* 5956:54-59, 2005.

---

Al-Hesayen A, Floras JS, Azevedo ER, Lopaschuk GD, **Parker JD**. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. *Eur J Heart Fail* 7:618-23, 2005.

Kubo I, **Parker JD**, Azevedo ER, et al. Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover. *Op cit* 7:878-881, 2005.

Al-Hesayen A, **Parker JD**. Renal handling of endothelin in patients with chronic heart failure. *Am J Cardiol* 95:532-534, 2005.

Katz SD, **Parker JD**, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. *Op cit* 95:36-42, 2005.

Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, **Parker JD**. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. *Circulation* 111:742-748, 2005.

Dragoni S, Gori T, Di Stolfo G, Sicuro S, Forconi S, **Parker JD**. Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion. A human study. *J Cardiovasc Pharm* 46:494-497, 2005.

Chauhan VS, Downar E, Nanthakumar K, **Parker JD** et al. Increased Ventricular Repolarization Heterogeneity in Patients with Ventricular Arrhythmia Vulnerability and Cardiomyopathy. *Am J Physiol Heart Circ Physiol*. 290:H79-86 [Epub 2005 Aug 19]

Gori T, Fineschi M, **Parker JD**, Forconi S. Current perspectives therapy with organic nitrates: newer ideas, more controversies. *Ital Heart J* 6:541-548, 2005.

Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, **Parker JD**, et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). *Am Heart J* 150:46-53, 2005.

---

Wong AH, Gottesman II, **Petronis A**. Phenotypic differences in genetically identical organisms: the epigenetic perspective. *Human Mol Genetics* 14(Suppl 1):R11-8; 2005.

Kaminsky ZA, Pependikyte V, Assadzadeh A, and **Petronis A**. Search for somatic DNA variation in the brain: investigation of the serotonin 2A receptor gene. *Mammal Genome*, 16:587-593, 2005.

Kaminsky ZA, Assadzadeh A, Flanagan J, and **Petronis A**. Single Nucleotide Extension Technology for Quantitative Site Specific Evaluation of metC/C in GC-Rich Regions. *Nucleic Acid Res* 33:e95, 2005.

Flanagan J, **Petronis A**. Pharmacoeigenetics: from the basic mechanisms to therapeutic applications. In W Kalow, UA Meyer, RF Tyndale (eds) Pharmacogenomics, 2nd Edition, Drugs and Pharmaceutical Sciences Vol 156, Taylor & Francis, New York. pp.

---

Teng, S, **Piquette-Miller M**. The Involvement of PXR in Hepatic Gene Regulation During Inflammation. *J. Pharmacol. Exper. Ther.* 312:841-848, 2005.

Hartman G, Vessileva V, **Piquette-Miller M**. Impact of Endotoxin-induced changes in P-glycoprotein Expression on the Disposition of Doxorubicin in Mice. *Drug Metab. Dispos* 33: 820-828, 2005.

Ho, EA, V. Vassileva, C. Allen and **Piquette-Miller, M**. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. *J Controlled Release* 104:181-191, 2005.

Wang, JH, S. Teng, D, Scollard, R Reilly and **Piquette-Miller, M**. Detection of P-glycoprotein activity using <sup>99m</sup>Tc-sestamibi imaging in endotoxemic rats. *J. Nucl. Med* 46:1537-45, 2005.

Grant, J, Blicher, M, **Piquette-Miller, M** and Allen C. Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel. *J Pharm Sci* 94:1512-27, 2005.

Jerkele, V, Kassack, M, Reilly, R, Wiese, M and **Piquette-Miller, M**. Functional comparison of single- and double-stranded mdr1 antisense oligodeoxy-nucleotides in human ovarian cancer cell lines. *JPPS*, 8:516-27, 2005.

---

## "R,S"

**Riddick DS**, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, Patterson AV, Stratford IJ, Morrow CS, Townsend AJ, Jounaidi Y, Chen C-S, Su T, Lu H, Schwartz PS, Waxman DJ: Cancer chemotherapy and drug metabolism. *Drug Metab. Dispos.* 33: 1083-1096; 2005.

**Riddick DS**, Perdew GH: AH receptor and AH receptor-dependent signaling. In Alaei M and Reiner E (eds) Dioxin 2005 Session Summaries. pp.27-29, 2005.

---

Hammer, GD, Parker, KL, **Schimmer, BP**: Transcriptional regulation of adrenocortical development. *Endocrinology* 146: 1018-1024 2005.

Parker, KL, **Schimmer, BP**. Embryology and genetics of the mammalian gonads and ducts. In: Neill J (ed.), Knobil and Neill's Physiology of Reproduction. vol 1, 3rd ed. Elsevier Inc. San Diego. pp. 313-336, 2005.

**Schimmer, BP**, Parker, KL. Adrenocorticotrophic hormone; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton L, Lazo J, Parker K (ed.), Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, Inc. NY. pp. 1587-1612, 2005.

Parker, KL, **Schimmer, BP**. Pituitary hormones and their hypothalamic releasing factors. Op cit. pp.14489-1510, 2005.

---

Remington G, **Seeman P**, Shammi C, et al: "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 25:611-613, 2005.

**Seeman P**: An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 162:1984-1985, 2005.

**Seeman P**, Ko F, Tallerico T: Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877-883, 2005.

**Seeman P**, Lasaga M: Dopamine agonist action of phencyclidine. Synapse 58:275-277, 2005.

**Seeman P**, Ko F, Willeit M, et al: Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Op cit 58:122-128, 2005.

**Seeman P**, Weinshenker D, Quirion R, et al: Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102:3513-3518, 2005.

Sumiyoshi T, **Seeman P**, Uehara T, et al: Increased proportion of high-affinity dopamine D2 receptors in rats with excitotoxic damage of the entorhinal cortex, an animal model of schizophrenia. Brain Res Mol Brain Res 140:116-119, 2005.

---

Grabis SD, Martin BR, Batman AM, Tyndale RT, **Sellers EM**, Damaj I, Nicotine physical dependence and tolerance in the mouse following chronic oral administration; Psychopharmacology 178:183-192, 2005.

Mwenifumbo JC, Myers MG, Wall TL, Lin SK, **Sellers EM**, Tyndale RF, Ethnic variation in CYP2A6\*7, CYP2A6\*8 and CYP 2A6\*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 15:189-192, 2005.

Shelepova T, Nafziger AN, Victory J, Kashuba ADM, Rowland E, Zhang Y, **Sellers EM**, Kearns G, Leeder S, Gaedigk A, Bertino JS, Effect of Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail J Clin Pharmacol 45:1413-1421, 2005.

Gilbert Evans SE, Ross LE, **Sellers EM**, Zhang WJ, Purdy RH, Romach MK. 3 $\alpha$ -Reduced Neuroactive steroids and their precursors during pregnancy and the postpartum period. *Gynecol Endocrinol* 21:268-279, 2005.

Malaiyandi V, **Sellers EM**, Tyndale RF Implications of CYP2A6 Genetic variation on smoking and nicotine dependence. *Clin Pharmacol Ther* 77:145-158, 2005.

---

Semple E, Madsen T, **Semple JW**. Quality of thrombin produced from the patient's own plasma using the TPD, a new Thrombin-processing Device. *J Extra Corpor Technol.* 37:196-200, 2005.

**Semple JW**, Freedman J. Autoimmune pathogenesis and autoimmune hemolytic anemia. *Semin Hematol.* 42:122-130, 2005

---

## "T"

Grabus SD, Martin BR, Batman AM, **Tyndale RF**, Sellers EM, Damaj MI. Nicotine physical dependence and tolerance in the mouse following chronic oral administration. *Psychopharmacology* 178:183-92, 2005.

Swan GE, Benowitz NL, Lessov CN, Jacob III P, **Tyndale RF**, Wilhelmsen K. Nicotine metabolism: The impact of CYP2A6 on estimates of additive genetic influence. *Pharmacogenet Genomics* 15:115-125, 2005.

Mwenifumbo JC, Myers MG, Wall TL, Lin S-K, Sellers EM, **Tyndale RF**. Ethnic variation in CYP2A6\*7, CYP2A6\*8 and CYP2A6\*10 as assessed with a novel genotyping method. *Op cit* 15:189-192, 2005.

Miksys SL, Cheung C, Gonzalez FJ, **Tyndale RF**. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. *Drug Metab Dispos* 33:1495-1502, 2005.

Malaiyandi V, Sellers EM, **Tyndale RF**. Implications of CYP2A6 Genetic Variation on Smoking and Nicotine Dependence. *Clin Pharmacol Ther* 77:145-58, 2005.

**Tyndale RF**, Sellers EM. Modifying the availability and metabolism of nicotine as therapeutic strategy. In *Understanding Nicotine and Tobacco Addiction*, Novartis Foundation Symposium, John Wiley, London 275: 235-248, 2005.

Al Koudsi N, **Tyndale RF**. The Genetic Influences on Smoking: A Brief Review. *Therap Drug Monitoring* 27:704-709, 2005.

Kalow W, Meyer UA, Tyndale RF. (eds) *Pharmacogenomics*. 2nd ed, *Drugs and the Pharmaceutical Sciences* series, vol 156, Taylor & Francis, New York, 2005.

---

## "U,V"

**Uetrecht J:** Current trends in autoimmunity. *Autoimmun. Rev.* 4:309-314, 2005.

**Uetrecht, J:** Role of drug metabolism for breaking tolerance and localization of drug hypersensitivity. *Toxicology* 209:113-118, 2005.

Pearce RE, **Uetrecht J**, Leeder JS, Pathways of Carbamazepine Bioactivation In Vitro II. The Role of Human Cytochrome P450 Enzymes in the Formation of 2-Hydroxyiminostilbene. *Drug Metab Dispos*, 33:1819-1826, 2005.

Shenton JM, Popovic M, Chen J, Masson MJ, **Uetrecht JP:** Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. *Chem. Res. Toxicol.* 18:1799-1813, 2005.

Seguin B, Boutros PC, Li X, Okey AB, **Uetrecht JP:** Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. *Op cit* 18:1193-1202, 2005.

Gardner I, Popovic M, Zahid N, **Uetrecht JP:** A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. *Op cit* 18:1384-1394, 2005.

---

## "W"

Jeng W, Wong AW, Ting-A-Kee R and **Wells PG.** Methamphetamine-enhanced embryonic oxidative DNA damage and neurodevelopmental deficits. *Free Radic. Biol. Med.* 39:317-326, 2005.

**Wells PG,** Bhuller, Y, Chen CS, et al. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. *Toxicol. Appl. Pharmacol.* 207(2S): 348-359, 2005.

---

**Wong AHC,** Likhodi O, Trakalo J, Yusuf M, Sinha A, Pato CN, Pato MT, Van Tol HHM, Kennedy JL: Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder, *Schizophrenia Res* 78:137-146, 2005.

**Wong AHC**, Lipska BK, Likhodi O, Boffa E, Weinberger DR, Kennedy JL, Van Tol HHM: Cortical gene expression in the neonatal ventral hippocampal lesion rat model, *op cit* 77:261-270, 2005.

**Wong AHC**, Gottesman I, Petronis A: Phenotypic differences in genetically identical organisms: the epigenetic perspective, *Human Mol Genetics* 14:R11-18, 2005.

De Luca V, Likhodi O, Van Tol HHM, Kennedy JL, **Wong AHC**: Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia, *Psychopharmacology* 183:378-382, 2005.

---

Pinto N, Halachmi N, Verjee Z, **Woodland C**, Klein J, and Koren G. Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. *Pediatric Res* 58:1284-1289, 2005.

---

**"X,Y,Z"**

**Zack M**, Stewart SH, Klein RM, Loba P, Fragopoulos F. Contingent gambling-drinking patterns and problem drinker status moderate implicit gambling-alcohol associations in problem gamblers. *J Gambling Stud* 21:325-354, 2005.

---